Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product delivered favorable results. The new drug, amycretin, similar to the company's blockbuster weight loss and diabetes drugs Wegovy and Ozempic,